Acquisition wake Post-acquisition by Labcorp, leverage expanded global network and cross-sell nonclinical testing services to Labcorp’s existing pharmaceutical and biotech clients, highlighting access to larger customer base and integrated offerings.

Regulatory readiness Highlight ISO/GLP/GMP and accreditation breadth across both Bedford facilities, enabling compliant GLP and non-GLP studies for medical devices and pharmaceuticals, a strong selling point for clients requiring regulatory-ready data packages.

Comprehensive services Promote end-to-end preclinical capabilities including in vivo, analytical, and in vitro testing, E&L, toxicology, PK/TK/ADME, microbiology validation, and histology, enabling one-stop risk assessment for device and drug developers.

Global reach Position Labcorp/Toxikon as a worldwide CRO option with multi-facility capabilities, extensive animal testing credentials, and a large active customer base across medical devices, pharma, and biotech sectors.

Emergency & proactive Capitalize on COVID-19 Task Force heritage to emphasize rapid response, risk mitigation, and staff safety programs, appealing to clients with urgent testing needs or supply-chain constraints.